Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical ...

WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...

The Company will present data from two Phase 3 trials (INTEGUMENT-1 and -2) demonstrating pooled safety and local tolerability of roflumilast cream 0.15% in adults and children down to age six with AD ...

One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical ...

Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and ...